Davies Nathan, Bogdanovica Ilze, McGill Shaun, Murray Rachael L
Nottingham Centre for Public Health and Epidemiology, School of Medicine, University of Nottingham, Nottingham City Hospital, Nottingham, NG5 1PB, UK.
Nottingham Centre for Public Health and Epidemiology, School of Medicine, University of Nottingham, Nottingham City Hospital, Nottingham NG5 1PB, UK and SPECTRUM consortium, Edinburgh, UK.
Nicotine Tob Res. 2025 Feb 24;27(3):369-377. doi: 10.1093/ntr/ntae206.
There is considerable interest in raising the age of sale of tobacco above the conventional age of 18 years. We systematically reviewed whether raising the minimum legal sales age of tobacco (MLSA) to 20 or above is associated with a reduced prevalence of smoking compared to an MLSA set at 18 or below.
Following a preregistered protocol on PROSPERO (ref: CRD42022347604), six databases of peer-reviewed journals were searched from January 2015 to April 2024. Backward and forward reference searching was conducted. Included studies assessed the association between MLSAs ≥20 with cigarette smoking or cigarette sales for those aged 11-20 years. Assessments on e-cigarettes were excluded. Pairs of reviewers independently extracted study data. We used ROBINS-I to assess the risk of bias and GRADE to assess the quality of evidence. Findings were also synthesized narratively.
Twenty-three studies were reviewed and 34 estimates of association were extracted. All extracted studies related to Tobacco 21 laws in the United States. Moderate quality evidence was found for reduced cigarette sales, moderate quality evidence was found for reduced current smoking for 18-20-year-olds, and low-quality evidence was found for reduced current smoking for 11-17-year-olds. The positive association was stronger for those with lower education. Study bias was variable.
There is moderate quality evidence that Tobacco 21 can reduce overall cigarette sales and current cigarette smoking amongst those aged 18-20 years. It has the potential to reduce health inequalities. Research in settings other than the United States is required.
This systematic review on raising the minimum legal sale age of tobacco to 20 or above demonstrates there is moderate quality evidence that such laws reduce cigarette sales and moderate quality evidence they reduce smoking prevalence amongst those aged 18-20 years compared to a minimum legal sale age of 18 years or below. The research highlights potential benefits in reducing health inequalities, especially for individuals from lower educational backgrounds. Studies are limited to the United States, highlighting a need for more global research to assess the impact of these policies in other settings.
将烟草销售年龄提高到传统的18岁以上引起了广泛关注。我们系统地回顾了与将烟草最低法定销售年龄(MLSA)设定为18岁及以下相比,将MLSA提高到20岁及以上是否与吸烟率降低相关。
根据在PROSPERO上预先注册的方案(参考文献:CRD42022347604),检索了2015年1月至2024年4月期间六个同行评审期刊数据库。进行了前后向参考文献检索。纳入的研究评估了MLSA≥20岁与11至20岁人群吸烟或香烟销售之间的关联。排除了对电子烟的评估。成对的评审员独立提取研究数据。我们使用ROBINS-I评估偏倚风险,使用GRADE评估证据质量。研究结果也进行了叙述性综合。
审查了23项研究,提取了34个关联估计值。所有提取的研究均与美国的《烟草21法案》有关。发现中等质量的证据表明香烟销售量减少,中等质量的证据表明18至20岁人群当前吸烟率降低,低质量的证据表明11至17岁人群当前吸烟率降低。对于受教育程度较低的人,这种正相关更强。研究偏倚各不相同。
有中等质量的证据表明,《烟草21法案》可以减少总体香烟销售量以及18至20岁人群当前的吸烟率。它有可能减少健康不平等现象。需要在美国以外的地区进行研究。
这项关于将烟草最低法定销售年龄提高到20岁及以上的系统评价表明,有中等质量的证据表明此类法律可减少香烟销售,并且与最低法定销售年龄为18岁及以下相比,有中等质量的证据表明它们可降低18至20岁人群的吸烟率。该研究突出了在减少健康不平等方面的潜在益处,特别是对于受教育程度较低的个人。研究仅限于美国,这突出表明需要进行更多的全球研究,以评估这些政策在其他地区的影响。